Publications 2021

 

Turkova A, White E, A. Mujuru H, R. Kekitiinwa A, M. Kityo C, Violari A, Lugemwa A, R. Cressey T, Musoke P, Variava E, F. Cotton M, Archary M, Puthanakit T, Behuhuma O, Kobbe R, B. Welch S, Bwakura-Dangarembizi M, Amuge P, Kaudha E, Barlow-Mosha L, Makumbi S, Ramsagar N, Ngampiyaskul C, Musoro G, Atwine L, Liberty A, Musiime V, Bbuye D, M. Ahimbisibwe G, Chalermpantmetagul S, Ali S, Sarfati T, Wynne B, Shakeshaft C, Colbers A, Klein N, Bernays S, Saïdi Y,Coelho A, Grossele T, Compagnucci A, Giaquinto C, Rojo P, Ford D, M. Gibb D for the ODYSSEY Trial Team. Dolutegravir as First- or Second-Line Treatment for HIV-1 Infection in Children. N Engl J Med.  2021 Dec 30. Lien PubMed

Gras J, Pillet M, Antoni G, Cua E, Charreau I, Raffi F, Chidiac C, Chas J, Tremblay C, Pasquet A, Spire B, Delaugerre C, Meyer L, Molina JM. Risk Factors for HIV Infection Among Men who have sex with men in the ANRS IPERGAY PrEP Trial. Sex Transm Inf. 2021 Oct 18 Lien PubMed

Berçot B, Charreau I, Clotilde R, Delaugerre C, Chidiac C, Pialoux G, Capitant C, Bourgeois-Nicolaos N, Raffi F, Pereyre S, Le Roy C, Senneville E, Meyer L, Bébéar C, Molina JM. High Prevalence and High Rate of Antibiotic Resistance of Mycoplasma genitalium Infections in Men who Have Sex with Men. A Sub-Study of the ANRS Ipergay PrEP Trial. Clin Infect Dis. 2021 Oct 5. Lien PubMed

Goldwirt L, Bauer R, Liegeon G, Charreau I, Delaugerre C, Cotte L, Pialoux G, Cua E, Laghzal A, Bushman L, Anderson P, Mourah S, Meyer L, Molina JM. Estimated pill intake with on demand PrEP with oral TDF/FTC using TFV-DP concentration in dried blot spots in the ANRS IPERGAY trial. Journal of Antimicrobial Chemotherapy. 2021 Sept 15  Lien PubMed

Chas j, Bauer B, Larabi IA, Peytavin G, Roux P, Cua E, Cotte L, Pasquet A, Capitant C, Meyer L,Raffi F, Spire B, Pialoux G , Molina JM, Alvarez JC. Evaluation of Drug Abuse by Hair Analysis and Self-Reported Use Among MSM Under PrEP: Results From a French Substudy of the ANRS-IPERGAY Trial. J Acquir Immune Defic Syndr. 2021 Apr 15. Lien PubMed

Chawki S, Charreau I, Gabassi A, Carette D, Cua E, Cotte L, Pialoux G; Pintado C, Meyer L, Delaugerre C, Molina JM. Inflammatory Markers During Early Treatment of Seroconverters in a Randomized Placebo-Controlled Trial of PrEP (ANRS-IPERGAY). Open Forum Infect Dis. 2021 Mar 20. Lien PubMed

Nguyen T, Valantin MA, Delaugerre C, Amiel C, Netzer E, L’Yavanc T, Ohayon M, Valin N, Day N, Kreplak G, Pialoux G, Calvez V, Molina JM, Marcelin AG, Todesco E. Low level of baseline resistance in recently HCV-infected men who have sex with men with high-risk behaviours. J Glob Antimicrob Resist 2021 Mar 24. Lien PubMed

Moore CL, Turkova A, Mujuru H, Kekitiinwa A, Lugemwa A, Kityo CM, Barlow-Mosha LN, Cressey TR, Violari A, Variava E, Cotton MF , Archary M , Compagnucci A , Puthanakit T, Behuhuma O, Saϊdi Y, Hakim J, Amuge P, Atwine L, Musiime V, Burger DM, Shakeshaft C, Giaquinto C, Rojo P, Gibb DM, Ford D, ODYSSEY Trial Team. ODYSSEY clinical trial design: a randomised global study to evaluate the efficacy and safety of dolutegravir-based antiretroviral therapy in HIV-positive children, with nested pharmacokinetic sub-studies to evaluate pragmatic WHO-weight-band based dolutegravir dosing. BMC Infect Dis. 2021 Jan 4. Lien PubMed